Literature DB >> 33738058

Myeloid Cell Leukemia-1 Inhibitors as Emerging Cancer Treatment.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2021        PMID： 33738058      PMCID： PMC7957920          DOI： 10.1021/acsmedchemlett.1c00099

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  5 in total

Review 1.  Recent advances in the development of Mcl-1 inhibitors for cancer therapy.

Authors:  Alexander W Hird; Adriana E Tron
Journal:  Pharmacol Ther       Date:  2019-02-18       Impact factor: 12.310

Review 2.  MCL-1 inhibitors - where are we now (2019)?

Authors:  Steven Fletcher
Journal:  Expert Opin Ther Pat       Date:  2019-10-14       Impact factor: 6.674

Review 3.  Development of Mcl-1 inhibitors for cancer therapy.

Authors:  Arvind Negi; Paul V Murphy
Journal:  Eur J Med Chem       Date:  2020-11-24       Impact factor: 6.514

Review 4.  Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology.

Authors:  Kexue Li
Journal:  Bioorg Med Chem Lett       Date:  2020-11-27       Impact factor: 2.823

Review 5.  Targeting MCL-1 in hematologic malignancies: Rationale and progress.

Authors:  Andrew H Wei; Andrew W Roberts; Andrew Spencer; Aaron Seth Rosenberg; David Siegel; Roland B Walter; Sean Caenepeel; Paul Hughes; Zach McIver; Khalid Mezzi; Phuong Khanh Morrow; Anthony Stein
Journal:  Blood Rev       Date:  2020-02-21       Impact factor: 8.250
  5 in total
  1 in total

Review 1.  Targeted Drug Delivery for Chronic Lymphocytic Leukemia.

Authors:  Makhloufi Zoulikha; Wei He
Journal:  Pharm Res       Date:  2022-03-07       Impact factor: 4.200
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.